El-Deeb, Ibrahim Mustafa Han, Dong Keun Kim, In Tae Lee, So Ha 2024-01-20T19:01:05Z 2024-01-20T19:01:05Z 2021-09-05 2010-07-20 0253-2964 https://pubs.kist.re.kr/handle/201004/131244 Phenylaminopyrimidines represent a large group of new selective anticancer agents, the majority of which exert their action through the inhibition of specific kinases. In this study, a new series of N-substituted-2-aminopyrimidines has been designed and synthesized. A selected group of the synthesized derivatives was screened at a single dose concentration of 10 mu M over a panel of 60 cancer cell-lines. Compound 12e has showed great inhibitory and strong lethal effect over almost all of the 60 cell-lines and accordingly was further tested in a 5-dose testing mode to determine its IC50 values, where it showed great efficacies with intermediate potencies over the tested cell-lines. The compound was also tested over a panel of 52 kinases to explore its kinase inhibitory profile, and was found to be a selective but moderate inhibitor over FLT3 kinase. English WILEY-V C H VERLAG GMBH ACUTE MYELOID-LEUKEMIA TYROSINE KINASE INHIBITOR FLT3 RECEPTOR POTENT DRUG New Phenylaminopyrimidine (PAP) Anticancer Lead Compound with High Efficacy: Design, Synthesis, and in vitro Screening Article 10.5012/bkcs.2010.31.7.1848 1 BULLETIN OF THE KOREAN CHEMICAL SOCIETY, v.31, no.7, pp.1848 - 1858 BULLETIN OF THE KOREAN CHEMICAL SOCIETY 31 7 1848 1858 scie scopus kci ART001525600 000280244700011 2-s2.0-77954913733 Chemistry, Multidisciplinary Chemistry Article ACUTE MYELOID-LEUKEMIA TYROSINE KINASE INHIBITOR FLT3 RECEPTOR POTENT DRUG Phenylaminopyrimidines Kinase inhibitor Cancer cell-lines Selectivity Cancer